贝舒地尔的购买渠道有哪些？

Besudil is a kinase inhibitor mainly used to treat patients with chronic graft-versus-host disease (chronic GVHD) in adults and children aged 12 years and older who have failed at least two previous lines of systemic therapy. Understanding its purchase channels, availability and price is of great significance to patients and their families who need to use this drug.

What are the purchasing channels for Besudil?

It is a prescription drug. The purchasing channels are relatively strict to ensure the safety and rational use of the drug. Patients and their families can obtain Besudil through the following legal channels:

Hospital pharmacy

Hospital pharmacy is one of the main channels to purchase Besudil. Patients need to go to the hospital pharmacy to purchase it with a valid prescription under the guidance of a doctor. Hospital pharmacies usually stock this drug, and pharmacists will provide professional medication guidance to ensure patients use it safely.

Legal retail pharmacies

Some legal retail pharmacies also provide besudil sales services. Patients need to bring the prescription issued by the doctor to a pharmacy licensed to sell prescription drugs to purchase it. When purchasing, it is recommended to consult a pharmacist about the storage, usage and precautions of the drug.

Online drug purchasing platforms

With the development of the Internet, some compliant online drug purchasing platforms also provide sales services for besudil. However, it should be noted that when choosing an online drug purchasing platform, you should ensure that it has legal drug sales qualifications and carefully read the platform's drug purchasing guide and medication instructions. At the same time, upload the prescription and follow the platform’s drug purchase process.

Whether purchasing Besudil through hospital pharmacies, legal retail pharmacies or online drug purchase platforms, patients should ensure that the drugs they purchase are genuine and use them in strict compliance with doctor's instructions.

Besudil’s marketing status

Besudil was first approved for marketing in the United States in 2021 for the treatment of specific patients with chronic GVHD. Its launch provides patients with new treatment options and marks an important advance in the treatment of chronic GVHD.

International marketing status

Currently, Besudil is mainly sold in the US market and has been approved by the US Food and Drug Administration (FDA). In other countries and regions, its listing status may vary due to regulatory policies and market demand. If patients need to know the marketing status of Besudil in a specific region, they can consult their local medical institution or drug regulatory department.

Domestic marketing situation

As far as the country is concerned, Besudil has not yet been officially approved for marketing. Therefore, domestic patients are currently unable to purchase the drug through formal channels. However, with the continuous improvement of my country's medical regulatory policies and the strengthening of international exchanges, Besudil may be approved and marketed domestically in the future. Patients can continue to pay attention to relevant drug regulatory developments and medical research progress.

The price of Besudil

The price of Besudil varies depending on factors such as region, sales channel, and purchase quantity. The price is for reference only. For patients, understanding the price information of the drug can help make financial preparations and medication planning.

The winning bid price of Besudil included in medical insurance is approximately US$5,633, and the price after reimbursement will be lower.

The specification of besudil mesylate produced by Sanofi in France is 200mg*30 tablets per box, and the price is approximately US$6,510 per box. In addition, Lucius’s generic version of Besudil is 200mg*30 pills per box, and the price is approximately US$558 per box.